PhD Scientific Days 2025

Conservative Medicine I.

Prospective Study on the Efficacy of Immunotherapy and Chemo-Immunotherapy at the Reformed Pulmonology Centre

Name of the presenter

Yahya Kamel

Institute/workplace of the presenter

Semmelweis University / Reformed Pulmonology Centre

Authors

Yahya Kamel¹, Lohinai Zoltán¹, Király Péter², Gálffy Gabriella¹

1: Semmelweis University / Reformed Pulmonology Centre
2: Reformed Pulmonology Centre

Text of the abstract

Introduction:

The application of immunotherapy and chemo-immunotherapy in non-small cell lung cancer (NSCLC) has significantly improved patient survival over the past decade. Our objective is to assess the clinicopathological parameters of patients treated at the Reformed Pulmonology Centre (Törökbálint) and to analyse the efficacy of the treatment.

Methods:

Between 1 April 2024 and 31 March 2025, we conducted a prospective study involving 55 patients with NSCLC treated with immunotherapy. We analysed patient sex, age, smoking habits, the presence of comorbidities (COPD, asthma, hypertension, heart failure, and diabetes mellitus), therapeutic response (responders vs non-responders), and documented adverse effects.

Results:

The study included 27 male and 28 female patients, of whom 2 had never smoked. Adenocarcinoma was diagnosed in 43 patients, squamous cell carcinoma in 9, and NSCLC (not otherwise specified) in 3 cases. High (>50%) tumoural Programmed Death-Ligand 1 (PD-L1) expression was observed in 29 patients (53%). Of the patients, 23 (42%) received mono-immunotherapy and 32 (58%) chemo-immunotherapy. COPD was present in 22 patients (40%), asthma in 4 (0.07%), hypertension in 34 (61%), and heart failure in 3 (0.05%). Type 1 diabetes mellitus was recorded in 2 patients (0.03%) and type 2 diabetes mellitus in 13 (23%). Evaluation of treatment efficacy in our prospective study is ongoing; to date, a favourable therapeutic response has been observed in 22 patients. A detailed analysis of these correlations will be presented in the lecture. Documented adverse effects included dermatitis (n=2) and hypothyroidism (n=2).

Conclusion:

Our findings support the importance of immunotherapy and chemo-immunotherapy in the treatment of non-small cell lung cancer. Consideration of comorbidities and adverse effects is essential when developing a treatment strategy.